Rare diseases
Investigational molecules
Locations
364 conditions with trials, the busiest first
1 201 trials across Europe, recruiting first
Study on the Safety and Effects of IPH6501 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
FranceStudy on the Effectiveness of Talquetamab and Teclistamab in First-Line Treatment for Transplant-Eligible Multiple Myeloma Patients
DenmarkStudy on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination
BelgiumStudy of BLU-263 and Azacitidine for Patients with Advanced Systemic Mastocytosis and Other KIT Altered Blood Cancers
BelgiumStudy of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients
PolandStudy on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care
BelgiumStudy on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises
BelgiumStudy on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients
FranceStudy of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma
CzechiaStudy on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)
BelgiumStudy on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)
FranceA Phase 4 Study of Crizanlizumab Treatment for Patients with Sickle Cell Disease Who Previously Participated in Novartis Clinical Trials
BelgiumThe therapies tested most often in Blood and lymphatic system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
